Nurix Therapeutics, Inc.
NRIX
Rank in Stocks
#6381
Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses... Nurix Therapeutics, Inc., a clinical stage biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule and antibody therapies for the treatment of cancer, inflammatory conditions, and other diseases. The company develops NX-5948, an orally bioavailable BTK degrader, that is in Phase 2 clinical trials for the treatment of relapsed or refractory B-cell malignancies and autoimmune diseases; NX-2127, an orally bioavailable Brutonโs tyrosine kinase (BTK) degrader, that is in Phase Phase 1a/1b clinical trials for the treatment of relapsed or refractory B-cell malignancies; and NX-1607, an orally bioavailable Casitas B-lineage lymphoma proto-oncogene-B (CBL-B) inhibitor, that is in Phase 1a/1b clinical trials to treat immuno-oncology indications. It is also developing NX-0479/GS-6791, a IRAK4 degrader for the treatment of rheumatoid arthritis and other inflammatory diseases. The company has a strategic collaboration agreement with Gilead Sciences, Inc. (Gilead), Sanofi S.A. (Sanofi), and Pfizer Inc. (Pfizer) for co-development and co-commercialization for multiple drug candidates. The company was formerly known as Nurix Inc. and changed its name to Nurix Therapeutics, Inc. in October 2018. Nurix Therapeutics, Inc. was incorporated in 2009 and is headquartered in Brisbane, California.
Share Price
$16.14
Last synced: 2026-11-09
Market Cap
$1.76B
Change (1 day)
5.49%
Change (1 year)
25.51%
Country
Stock data: Financial Modeling PrepยทUpdated ยทNot investment adviceยทHow we calculate this
Trade Nurix Therapeutics, Inc. (NRIX)
Category
Healthcare
Operating Margin for Nurix Therapeutics, Inc. (NRIX)
Operating Margin as of November 2026 TTM: 41.27%
According to Nurix Therapeutics, Inc.'s latest financial reports, its current operating margin (TTM) is 41.27%. At the end of 2025 the company had an operating margin of -340.16%.
Operating Margin history for Nurix Therapeutics, Inc. from 2018 to 2026
Operating Margin at the end of each year
| Year | Operating Margin | Change |
|---|---|---|
| 2026 (TTM) | 41.27% | -112.13% |
| 2025 | -340.16% | -12.90% |
| 2024 | -390.52% | 93.89% |
| 2023 | -201.41% | -57.69% |
| 2022 | -476.01% | 20.13% |
| 2021 | -396.26% | 8.67% |
| 2020 | -364.66% | 410.30% |
| 2019 | -71.46% | 174.74% |
| 2018 | -26.01% | 0.00% |
Operating Margin for similar companies or competitors
| Company | Operating Margin | Operating Margin Difference | Country |
|---|---|---|---|
| 38.59% | -99.06% |
US
|
|
| -149.01% | -103.61% |
US
|
|
| 25.57% | -99.38% |
AU
|
|
| 31.23% | -99.24% |
BE
|
|
| 29.35% | -99.29% |
NL
|
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.
Questions about Nurix Therapeutics, Inc.'s operating margin
What is Nurix Therapeutics, Inc.'s operating margin?
Nurix Therapeutics, Inc.'s operating margin is 41.27%, as of Nov 2026.
What was Nurix Therapeutics, Inc.'s operating margin in 2025?
In 2025, Nurix Therapeutics, Inc.'s operating margin was -340.16%, compared with -390.52% in 2024.
How has Nurix Therapeutics, Inc.'s operating margin changed since 2020?
From 2020 to 2025, Nurix Therapeutics, Inc.'s operating margin was highest in 2023 (-201.41%) and lowest in 2022 (-476.01%).
How does Nurix Therapeutics, Inc.'s operating margin compare with similar companies?
Nurix Therapeutics, Inc.'s operating margin (41.27%) is higher than that of all 5 similar companies listed above. The highest among them is Vertex Pharmaceuticals Incorporated, with 38.59%.